Literature DB >> 30085294

Systemic Toxicity of Smokeless Tobacco Products in Mice.

Marina V Malovichko1, Iris Zeller1, Tatiana V Krivokhizhina1, Zhengzhi Xie1, Pawel Lorkiewicz1, Abhinav Agarwal1, Nalinie Wickramasinghe1, Srinivas D Sithu1, Jasmit Shah1, Timothy O'Toole1, Shesh N Rai1, Aruni Bhatnagar1, Daniel J Conklin1, Sanjay Srivastava1.   

Abstract

Introduction: Smokeless tobacco products such as snuff and snus are used worldwide. However, little is known about the systemic and cardiovascular toxicity of smokeless tobacco exposure.
Methods: Biomarkers of endothelial activation and injury, immune functions, platelet activation and insulin resistance were measured in 8-week old male C57BL/6 mice exposed to commercial snuff, CRP-2 reference snuff, commercial snus, CRP-1 reference snus, and nicotine in drinking water (100 µg/mL) for 4, 12, and 24 weeks.
Results: Twenty-four weeks of exposure to smokeless tobacco products or nicotine significantly decreased the levels of circulating Flk+/Sca+ endothelial progenitor cells. Twelve and 24 weeks of exposure to all the smokeless tobacco products and nicotine significantly decreased the levels of circulating CD19+ B cells, CD4+ T cells, CD8+ T cells, and CD11b+ monocytes, whereas 4 weeks of exposure to Camel snus and Copenhagen snuff significantly depleted the levels of peripheral blood CD19+ B cells and CD11b+ monocytes. Twenty-four weeks of exposure to smokeless tobacco products or nicotine significantly decreased plasma IFNγ levels. However, plasma TNFα levels were significantly increased in mice exposed to Copenhagen snuff or nicotine for 24 weeks. This was accompanied by a five to sevenfold increase in the hepatic expression of TNFα. Neither smokeless products nor nicotine affected plasma lipoproteins, platelet activation, or systemic insulin sensitivity. Conclusions: Chronic exposure to snuff and snus suppresses circulating levels of EPCs, endothelial microparticles and immune cells, but increases plasma TNF-α levels. These effects of smokeless tobacco products are attributable, at least in part, to nicotine. Implications: Exposure to smokeless tobacco products results in the depletion of endothelial progenitor cells, which may impair the endothelium repair. Suppression of the circulating levels of immune cells upon exposure to smokeless tobacco products may increase the susceptibility to secondary infection. Increased formation of proinflammatory cytokines such as TNFα by nicotine or Copenhagen snuff may lead to vascular inflammation and thereby exacerbate atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30085294      PMCID: PMC6329408          DOI: 10.1093/ntr/ntx230

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  11 in total

1.  Electronic cigarette-generated aldehydes: The contribution of e-liquid components to their formation and the use of urinary aldehyde metabolites as biomarkers of exposure.

Authors:  Daniel J Conklin; Mumiye A Ogunwale; Yizheng Chen; Whitney S Theis; Michael H Nantz; Xiao-An Fu; Lung-Chi Chen; Daniel W Riggs; Pawel Lorkiewicz; Aruni Bhatnagar; Sanjay Srivastava
Journal:  Aerosol Sci Technol       Date:  2018-08-23       Impact factor: 2.908

2.  Effect of vinyl chloride exposure on cardiometabolic toxicity.

Authors:  Igor N Zelko; Breandon S Taylor; Trinath P Das; Walter H Watson; Israel D Sithu; Banrida Wahlang; Marina V Malovichko; Matthew C Cave; Sanjay Srivastava
Journal:  Environ Toxicol       Date:  2021-10-30       Impact factor: 4.109

3.  Subclinical markers of cardiovascular toxicity of benzene inhalation in mice.

Authors:  Marina V Malovichko; Wesley T Abplanalp; Samantha A McFall; Breandon S Taylor; Nalinie S Wickramasinghe; Israel D Sithu; Igor N Zelko; Shizuka Uchida; Bradford G Hill; Saurin R Sutaria; Michael H Nantz; Aruni Bhatnagar; Daniel J Conklin; Timothy E O'Toole; Sanjay Srivastava
Journal:  Toxicol Appl Pharmacol       Date:  2021-10-05       Impact factor: 4.460

Review 4.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

Review 5.  The effect of emerging tobacco related products and their toxic constituents on thrombosis.

Authors:  Ahmed B Alarabi; Patricia A Lozano; Fadi T Khasawneh; Fatima Z Alshbool
Journal:  Life Sci       Date:  2021-12-23       Impact factor: 6.780

6.  Evaluation of systemic inflammatory and thrombotic markers of cardiovascular risk among young Indian oral tobacco users.

Authors:  Dhananjay V Zutshi; Mohit D Gupta; M P Girish; Ankit Bansal; Vishal Batra; Rajni Saijpaul; Bhawna Mahajan; Sanjay Tyagi; Jamal Yusuf; Saibal Mukhopadhyay
Journal:  Indian Heart J       Date:  2020-08-11

7.  Panel of significant risk factors predicts early stage gastric cancer and indication of poor prognostic association with pathogens and microsatellite stability.

Authors:  Payel Chakraborty; Souvik Ghatak; Saia Chenkual; Lalawmpuii Pachuau; John Zohmingthanga; Zothankima Bawihtlung; Lalfakzuala Khenglawt; Jeremy L Pautu; Arindam Maitra; Lalchhandama Chhakchhuak; Nachimuthu Senthil Kumar
Journal:  Genes Environ       Date:  2021-02-10

Review 8.  Tobacco Use: A Major Risk Factor of Intracerebral Hemorrhage.

Authors:  Sunjoo Cho; Ashish K Rehni; Kunjan R Dave
Journal:  J Stroke       Date:  2021-01-31       Impact factor: 6.967

9.  A novel evaluation of endothelial dysfunction ex vivo: "Teaching an Old Drug a New Trick".

Authors:  Lexiao Jin; Daniel J Conklin
Journal:  Physiol Rep       Date:  2021-11

10.  Evaluation of C-reactive protein and hematological parameters in smokeless tobacco users: A comparative cross-sectional study.

Authors:  Sikander Munir Memon; Naresh Kumar; Aneela Atta Ur Rahman; Binafsha Manzoor Syed
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.